Human papillomavirus vaccine recombinant bivalent (GlaxoSmithKline)

重组双价人乳头瘤病毒吸附疫苗（葛兰素史克）

Report date: 2024/01/04 17:54:46

Base Information

Drug NameHuman papillomavirus vaccine recombinant bivalent (GlaxoSmithKline)
Drug Alias Name人类乳头状瘤病毒疫苗重组二价 - 葛兰素史克/MedImmuneHPV-16/18 VLP AS04 vaccine重组人乳头瘤病毒2价疫苗HPV-16/18 vaccineHPV vaccine +[10] 
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > National Immunization Program > Non-immunization program vaccine(Class II)Vaccines > Development/production technology > Genetically engineered subunit vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPrecancerous ConditionsUterine Cervical NeoplasmsCervical Intraepithelial Neoplasia +[6] 
Global Approved IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Approved Indications in ChinaUterine Cervical NeoplasmsCervical Intraepithelial Neoplasia
Original Approved Country/TerritoryEU
Original Approved Date2007/09/20
Country/TerritoryBelgiumCanadaUnited States +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline PlcMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxosmithkline Biologicals SA
Inactive CompaniesGlaxosmithkline Biological Products Co LtdMedimmune LlcGlaxosmithkline (China) Investment Co Ltd
Active IndicationsUterine Cervical NeoplasmsCervical Intraepithelial NeoplasiaPapillomavirus Infections
Inactive IndicationsPrecancerous ConditionsAdenocarcinoma in SituMeningococcal Infections

Other Information

ATC CodeJ07BM02
Related LinksN/A